351 related articles for article (PubMed ID: 27614009)
1. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.
Shi J; Wang X; Nguyen JH; Bleske BE; Liang Y; Liu L; Zhu HJ
Biochem Pharmacol; 2016 Nov; 119():76-84. PubMed ID: 27614009
[TBL] [Abstract][Full Text] [Related]
2. Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis.
Laizure SC; Parker RB; Herring VL; Hu ZY
Drug Metab Dispos; 2014 Feb; 42(2):201-6. PubMed ID: 24212379
[TBL] [Abstract][Full Text] [Related]
3. Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation.
Laizure SC; Chen F; Farrar JE; Ali D; Yang B; Parker RB
Drug Metab Pharmacokinet; 2022 Dec; 47():100479. PubMed ID: 36375226
[TBL] [Abstract][Full Text] [Related]
4. Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.
Shi J; Wang X; Eyler RF; Liang Y; Liu L; Mueller BA; Zhu HJ
Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):555-561. PubMed ID: 27228223
[TBL] [Abstract][Full Text] [Related]
5. Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation.
Shi J; Wang X; Nguyen J; Wu AH; Bleske BE; Zhu HJ
Drug Metab Dispos; 2016 Apr; 44(4):554-9. PubMed ID: 26817948
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of dabigatran etexilate interindividual variability.
Dimatteo C; D'Andrea G; Vecchione G; Paoletti O; Cappucci F; Tiscia GL; Buono M; Grandone E; Testa S; Margaglione M
Thromb Res; 2016 Aug; 144():1-5. PubMed ID: 27261537
[TBL] [Abstract][Full Text] [Related]
7. The Distribution of the Genotypes of
Abdrakhmanov A; Akilzhanova A; Shaimerdinova A; Zhalbinova M; Tuyakova G; Abildinova S; Albayev R; Ainabekova B; Chinybayeva A; Suleimen Z; Bekbossynova M
Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372371
[TBL] [Abstract][Full Text] [Related]
8. Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease.
Sychev D; Skripka A; Ryzhikova K; Bochkov P; Shevchenko R; Krupenin P; Ivashchenko D; Kogay V; Listratov A; Krainyaya A; Gurinovich O; Sokolova A; Napalkov D; Fomin V
Drug Metab Pers Ther; 2020 Mar; 35(1):. PubMed ID: 32134727
[TBL] [Abstract][Full Text] [Related]
9. Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers.
Wang X; Her L; Xiao J; Shi J; Wu AH; Bleske BE; Zhu HJ
Clin Transl Sci; 2021 Jul; 14(4):1380-1389. PubMed ID: 33660934
[TBL] [Abstract][Full Text] [Related]
10. CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors.
Wang X; Wang G; Shi J; Aa J; Comas R; Liang Y; Zhu HJ
Pharmacogenomics J; 2016 Jun; 16(3):220-30. PubMed ID: 26076923
[TBL] [Abstract][Full Text] [Related]
11. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.
Merali Z; Ross S; Paré G
Drug Metabol Drug Interact; 2014; 29(3):143-51. PubMed ID: 24988246
[TBL] [Abstract][Full Text] [Related]
12. Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism.
Hu ZY; Parker RB; Herring VL; Laizure SC
Anal Bioanal Chem; 2013 Feb; 405(5):1695-704. PubMed ID: 23239178
[TBL] [Abstract][Full Text] [Related]
13. Genetic determinants of dabigatran plasma levels and their relation to bleeding.
Paré G; Eriksson N; Lehr T; Connolly S; Eikelboom J; Ezekowitz MD; Axelsson T; Haertter S; Oldgren J; Reilly P; Siegbahn A; Syvanen AC; Wadelius C; Wadelius M; Zimdahl-Gelling H; Yusuf S; Wallentin L
Circulation; 2013 Apr; 127(13):1404-12. PubMed ID: 23467860
[TBL] [Abstract][Full Text] [Related]
14. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation.
Zhu HJ; Wang X; Gawronski BE; Brinda BJ; Angiolillo DJ; Markowitz JS
J Pharmacol Exp Ther; 2013 Mar; 344(3):665-72. PubMed ID: 23275066
[TBL] [Abstract][Full Text] [Related]
15. Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators.
Her L; Zhu HJ
Drug Metab Dispos; 2020 Mar; 48(3):230-244. PubMed ID: 31871135
[TBL] [Abstract][Full Text] [Related]
16. Contributions of Cathepsin A and Carboxylesterase 1 to the Hydrolysis of Tenofovir Alafenamide in the Human Liver, and the Effect of CES1 Genetic Variation on Tenofovir Alafenamide Hydrolysis.
Li J; Shi J; Xiao J; Tran L; Wang X; Zhu HJ
Drug Metab Dispos; 2022 Mar; 50(3):243-248. PubMed ID: 34933885
[TBL] [Abstract][Full Text] [Related]
17. Physiologically-Based Pharmacokinetic Modeling to Predict Methylphenidate Exposure Affected by Interplay Among Carboxylesterase 1 Pharmacogenetics, Drug-Drug Interactions, and Sex.
Xiao J; Shi J; Thompson BR; Smith DE; Zhang T; Zhu HJ
J Pharm Sci; 2022 Sep; 111(9):2606-2613. PubMed ID: 35526575
[TBL] [Abstract][Full Text] [Related]
18. Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects.
Her LH; Wang X; Shi J; Choi HJ; Jung SM; Smith LS; Wu AH; Bleske BE; Zhu HJ
Br J Clin Pharmacol; 2021 Dec; 87(12):4691-4700. PubMed ID: 33963573
[TBL] [Abstract][Full Text] [Related]
19. The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin.
Qian Y; Gilliland TK; Markowitz JS
Chem Biol Interact; 2020 Jan; 316():108914. PubMed ID: 31837295
[TBL] [Abstract][Full Text] [Related]
20. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation.
Ji Q; Zhang C; Xu Q; Wang Z; Li X; Lv Q
Br J Clin Pharmacol; 2021 May; 87(5):2247-2255. PubMed ID: 33179295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
